Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events
Sign Up to like & getrecommendations! Published in 2025 at "American Journal of Hematology"
DOI: 10.1002/ajh.70015
Abstract: Belantamab mafodotin (belamaf)‐containing regimens are effective treatment options for patients with relapsed and/or refractory multiple myeloma. Ocular events are a common adverse effect of belamaf treatment, which can be managed by physicians, following appropriate training,… read more here.
Keywords: practical guidance; ocular events; guidance clinical; belantamab mafodotin ... See more keywords
Real-world characteristics and outcomes of patients with multiple myeloma treated with belantamab mafodotin: a German claims data study
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06427-6
Abstract: In the DREAMM-2 trial, belantamab mafodotin (belamaf) monotherapy demonstrated clinical activity and a manageable safety profile in pretreated patients with relapsed/refractory multiple myeloma (RRMM). Real-world evidence on this patient population is scarce. This study describes… read more here.
Keywords: multiple myeloma; treatment; belamaf; real world ... See more keywords
Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study
Sign Up to like & getrecommendations! Published in 2025 at "Targeted Oncology"
DOI: 10.1007/s11523-025-01174-0
Abstract: In the phase 3 DREAMM-8 study (NCT04484623), belantamab mafodotin (anti-B-cell maturation antigen [BCMA] antibody-drug conjugate with a monomethyl auristatin F payload) with pomalidomide and dexamethasone (BPd) showed significant progression-free survival benefit in second-line or later… read more here.
Keywords: dreamm; response; belantamab; belantamab mafodotin ... See more keywords
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01110-x
Abstract: to a relatively new class of therapeutics characterized by a chemical fusion of monoclonal antibodies to a conventional chemotherapeutic drug which is called antibody-drug conjugates (ADCs) [1]. The rationale is to limit systemic toxicity and… read more here.
Keywords: multiple myeloma; belantamab mafodotin; therapy;
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01155-y
Abstract: Belantamab mafodotin is a fi rst-in-class humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody conjugated to the microtubule inhibitor monomethyl auristatin F [1]. Preclinical studies showed belantamab mafodotin interacts synergistically with standard-of-care agents for multiple… read more here.
Keywords: mafodotin; trial; phase dreamm; belantamab mafodotin ... See more keywords
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01212-0
Abstract: Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti–B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval for patients with RRMM who… read more here.
Keywords: dreamm; mafodotin; refractory multiple; belantamab mafodotin ... See more keywords
Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
Sign Up to like & getrecommendations! Published in 2022 at "Cornea"
DOI: 10.1097/ico.0000000000003162
Abstract: Supplemental Digital Content is Available in the Text. Abstract: Emerging monoclonal antibody therapies are assuming greater importance in the management of severe and refractory forms of immunity-driven and oncological disorders. However, some have been found… read more here.
Keywords: adverse ocular; belantamab mafodotin; etiology; management ... See more keywords
Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.16133
Abstract: To evaluate relationships between plasma concentrations of belantamab mafodotin, total monoclonal antibody, and its payload and changes in electrocardiogram (ECG) parameters in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and DREAMM‐2 studies. read more here.
Keywords: dreamm; multiple myeloma; refractory multiple; belantamab mafodotin ... See more keywords
Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18298
Abstract: Belantamab mafodotin (BLMF) is a B‐cell maturation antigen‐directed antibody‐drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF‐induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively… read more here.
Keywords: advanced multiple; belantamab mafodotin; blmf; toxicity ... See more keywords
Abstract 6711: Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergizein vitroand potentiatein vivoanti-tumor activity in multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-6711
Abstract: Multiple myeloma (MM) is a hematological malignancy that affects plasma cells and leads to devastating clinical features. Typically, front-line and relapsed/refractory multiple myeloma (RRMM) treatments comprise standard of care (SOC) combinations that include proteasome inhibitors… read more here.
Keywords: lenalidomide pomalidomide; multiple myeloma; belantamab mafodotin; cell ... See more keywords
Belantamab mafodotin for relapsed or refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221086265
Abstract: Objective: Refractory multiple myeloma (MM) presents poor responses to therapies. New drugs for highly pretreated MM are a hope for this clinical context with limited treatment options. We developed a comparative commentary on the evidence… read more here.
Keywords: mafodotin; relapsed refractory; belantamab mafodotin; refractory multiple ... See more keywords